Although there is no established treatment strategy for ALL with concurrent CRLF2 deregulation and HHD, it has been reported that when patients with BCR-ABL1-like ALL were treated according to their MRD status, the prognosis was not different between patients with and without BCR-ABL1-like ALL [13]. The gene discussed is CRLF2; the disease is acute lymphoblastic leukemia.